Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) shares were up 20.6% during mid-day trading on Tuesday . The company traded as high as $2.38 and last traded at $2.11, with a volume of 7,237,620 shares trading hands. The stock had previously closed at $1.75.

CNAT has been the topic of a number of research analyst reports. Zacks Investment Research upgraded shares of Conatus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 target price on the stock in a research report on Wednesday, August 10th. Brean Capital set a $7.00 target price on shares of Conatus Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 5th. Roth Capital initiated coverage on shares of Conatus Pharmaceuticals in a research report on Friday, July 1st. They issued a “buy” rating on the stock. Finally, FBR & Co restated an “outperform” rating and issued a $16.00 target price on shares of Conatus Pharmaceuticals in a research report on Tuesday, August 30th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Conatus Pharmaceuticals presently has an average rating of “Buy” and an average price target of $9.41.

The company has a 50-day moving average price of $1.93 and a 200 day moving average price of $2.23. The firm’s market cap is $45.83 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/conatus-pharmaceuticals-inc-cnat-trading-up-20-6.html

Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its quarterly earnings results on Wednesday, August 3rd. The biotechnology company reported ($0.30) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.38) by $0.08. During the same quarter in the previous year, the firm earned ($0.31) EPS. Equities research analysts forecast that Conatus Pharmaceuticals Inc. will post ($1.34) EPS for the current year.

Several hedge funds have recently made changes to their positions in the stock. AXA raised its stake in Conatus Pharmaceuticals by 1.4% in the second quarter. AXA now owns 1,085,775 shares of the biotechnology company’s stock worth $2,237,000 after buying an additional 14,939 shares during the period. Vanguard Group Inc. raised its stake in Conatus Pharmaceuticals by 3.5% in the second quarter. Vanguard Group Inc. now owns 448,938 shares of the biotechnology company’s stock worth $925,000 after buying an additional 15,300 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in Conatus Pharmaceuticals by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 86,296 shares of the biotechnology company’s stock worth $178,000 after buying an additional 1,668 shares during the period. Institutional investors own 22.80% of the company’s stock.

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

5 Day Chart for NASDAQ:CNAT

Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.